Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Coronavirus Vaccine Progress, A New CAR-T And A Big Oncology Deal

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major industry developments in the business week ended 31 July 2020.

Further progress with multiple coronavirus vaccines, a new CAR-T therapy in the US, and a breakdown of a huge new oncology deal are covered this week.

Stories mentioned in this episode:

(Also see "Can An Antibody Cocktail Block COVID-19 Infection? Regeneron’s Warp Speed Research Aims To Find Out Soon" - Scrip, 27 Jul, 2020.)

(Also see "China Advances Two Coronavirus Vaccines Into Phase III" - Scrip, 28 Jul, 2020.)

(Also see "Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy" - Scrip, 28 Jul, 2020.)

(Also see "Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First" - Scrip, 26 Jul, 2020.)

(Also see "Oncology Deal-Making The Daiichi Way" - Scrip, 27 Jul, 2020.)



Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts